Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Hepatocellular 42Carcinoma, Renal Cell 12Neoplasms 11Liver Neoplasms 8Carcinoma 5Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Leukemia, Myeloid, Acute 3Kidney Neoplasms 3Melanoma 2Hepatoblastoma 2Vaccinia 1Thyroid Neoplasms 1Sarcoma, Myeloid 1Recurrence 1Radiotherapy 1Pancreatic Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Liver Diseases 1Fibrolamellar hepatocellular carcinoma 1Digestive System Neoplasms 1Digestive System Diseases 1Desmoid Tumors 1Breast Neoplasms 1Advanced Liver Cancer 1Adenocarcinoma 1

Interventions

Iodine-131 3Thyrotropin Alfa 2vandetanib 1lenvatinib 1fosbretabulin 1combretastatin 1cabozantinib 1Thyroidectomy 1Sorafenib 1Ropivacaine 1Radiotherapy 1Paclitaxel 1Neck Dissection 1Metformin 1Epinephrine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Thyroid Neoplasms × Sorafenib × Clear all
NCT00984282 2018-09-13

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Bayer

Phase 3 Completed
417 enrolled 22 charts
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡